Laboratory Oncology Unit, Dr. B.R.A.IRCH, All India Institute of Medical Sciences, New Delhi, India.
Department of Computational Biology, Indraprastha Institute of Information Technology-Delhi (IIIT-D), Delhi, India.
Blood Cancer J. 2020 Jan 13;10(1):6. doi: 10.1038/s41408-019-0272-y.
Abnormal expression patterns of regulatory small non-coding RNA (sncRNA) molecules such as microRNAs (miRs), piwi-interacting RNAs (piRNAs), and small nucleolar RNAs (snoRNAs) play an important role in the development and progression of cancer. Identification of clinically relevant sncRNA signatures could, therefore, be of tremendous translational value. In the present study, genome-wide small RNA sequencing identified a unique pattern of differential regulation of eight miRs in Chronic Lymphocytic Leukemia (CLL). Among these, three were up-regulated (miR-1295a, miR-155, miR-4524a) and five were down-regulated (miR-30a, miR-423, miR-486*, let-7e, and miR-744) in CLL. Altered expression of all these eight differentially expressed miRs (DEMs) was validated by RQ-PCR. Besides, seven novel sequences identified to have elevated expression levels in CLL turned out to be transfer RNA (tRNA)/piRNAs (piRNA-30799, piRNA-36225)/snoRNA (SNORD43) related. Multivariate analysis showed that miR-4524a (HR: 1.916, 95% CI: 1.080-3.4, p value: 0.026) and miR-744 (HR: 0.415, 95% CI: 0.224-0.769, p value: 0.005) were significantly associated with risk and time to first treatment. Further investigations could help establish the scope of integration of these DEM markers into risk stratification designs and prognostication approaches for CLL.
异常表达的调控性小非编码 RNA(sncRNA)分子,如 microRNAs(miRs)、piwi 相互作用 RNA(piRNAs)和小核仁 RNA(snoRNAs),在癌症的发生和发展中起着重要作用。因此,鉴定具有临床相关性的 sncRNA 特征可能具有巨大的转化价值。在本研究中,全基因组小 RNA 测序鉴定了慢性淋巴细胞白血病(CLL)中 8 种 miRNA 差异调节的独特模式。其中,3 种上调(miR-1295a、miR-155、miR-4524a),5 种下调(miR-30a、miR-423、miR-486*、let-7e 和 miR-744)。通过 RQ-PCR 验证了这 8 种差异表达 miRNA(DEM)的表达改变。此外,在 CLL 中鉴定出的七种表达水平升高的新序列,结果显示为转移 RNA(tRNA)/piRNA(piRNA-30799、piRNA-36225)/snoRNA(SNORD43)相关。多变量分析显示,miR-4524a(HR:1.916,95%CI:1.080-3.4,p 值:0.026)和 miR-744(HR:0.415,95%CI:0.224-0.769,p 值:0.005)与风险和首次治疗时间显著相关。进一步的研究可以帮助确定这些 DEM 标志物在 CLL 风险分层设计和预后评估中的整合范围。